Xoma Corp. (XOMA) Given Outperform Rating at Wedbush
Xoma Corp. (NASDAQ:XOMA)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a report issued on Friday. They presently have a $3.00 price target on the stock, up from their previous price target of $1.42. Wedbush’s target price would indicate a potential upside of 429.66% from the company’s current price.
XOMA has been the topic of several other research reports. Jefferies Group reaffirmed a “hold” rating on shares of Xoma Corp. in a research report on Friday, August 5th. Zacks Investment Research raised Xoma Corp. from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Wednesday, August 10th. Finally, Cowen and Company reaffirmed a “neutral” rating on shares of Xoma Corp. in a research report on Wednesday, August 10th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Xoma Corp. has a consensus rating of “Hold” and an average price target of $1.81.
Shares of Xoma Corp. (NASDAQ:XOMA) traded down 15.1334% during mid-day trading on Friday, hitting $0.5664. The company had a trading volume of 4,439,442 shares. The company has a 50-day moving average price of $0.61 and a 200-day moving average price of $0.68. Xoma Corp. has a 1-year low of $0.44 and a 1-year high of $2.03. The company has a market capitalization of $68.30 million, a price-to-earnings ratio of 51.4909 and a beta of 2.70.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/16/xoma-corp-xoma-given-outperform-rating-at-wedbush.html
Xoma Corp. (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.01. The company earned $0.40 million during the quarter, compared to the consensus estimate of $0.84 million. During the same quarter in the prior year, the business posted ($0.20) earnings per share. On average, equities analysts anticipate that Xoma Corp. will post ($0.47) EPS for the current year.
Hedge funds have recently modified their holdings of the stock. Paloma Partners Management Co acquired a new stake in shares of Xoma Corp. during the second quarter valued at approximately $185,000. Spark Investment Management LLC raised its position in shares of Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock worth $112,000 after buying an additional 102,400 shares during the period. Vanguard Group Inc. raised its position in shares of Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock worth $2,934,000 after buying an additional 871,594 shares during the period. Wedbush Securities Inc. raised its position in shares of Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock worth $223,000 after buying an additional 15,827 shares during the period. Finally, Bellevue Group AG purchased a new position in shares of Xoma Corp. during the first quarter worth about $174,000. Hedge funds and other institutional investors own 17.13% of the company’s stock.
Xoma Corp. Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for Xoma Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Xoma Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.